|
Market Cap (4-Jun) $3,159,507 (1,963rd) |
Close (30-Jun) $0.028 |
Volume (30-Jun) 42,322 |
Shortsold (5-Apr) 9,554 (0.01%) (569th) |
|
52w High $0.020 |
52w Low $0.004 |
P/E - |
EPS -0.01 |
ANR released this announcement to the ASX on 24 February 2022, 9:59. The announcement is marked as price sensitive, and is 20 page(s) in length and 423.02kb in size.
You can view all announcements from ANR and see how they appear on a price chart on the announcements page.
At the date of this announcement, ANR was 0.003% short sold according to ASIC data. It was ranked the 598th most shorted stock on the ASX. It is now ranked as the 569th most shorted stock on the ASX with 0.006% of total shares short sold as of the latest reported data (05 April 2024).
| Other Recent Announcements from ANR | |
|---|---|
| Anatara Update on GaRP Irritable Bowel Syndrome Trial | 6 June 2023, 8:19 |
| Anatara Investor Presentation | 8 May 2023, 10:44 |
| Registered Office Change | 20 April 2023, 11:51 |
| Half Year Accounts | 24 February 2022, 9:59 |
| Clinical Trials Update | 17 February 2022, 15:03 |
| Appendix 4C and Q2 FY22 Activities Report | 28 January 2022, 9:10 |
| Appendix 4C and Q2 FY22 Activities Report | 27 January 2022, 16:14 |
You must be logged in to post a reply.
Anatara Lifesciences 